ประกวดราคาการจัดซื้อเวชภัณฑ์ยา Trastuzumab 440 mg จำนวน 60 vial
trastuzumab In 2006, trastuzumab plus chemotherapy was approved to treat patients after their HER2-overexpressing breast tumors were surgically removed
In the DESTINY-Breast04 trial, trastuzumab deruxtecan showed superior activity over standard chemotherapy options in patients with HER2-low advanced breast trastuzumab In the DESTINY-Breast04 trial, trastuzumab deruxtecan showed superior activity over standard chemotherapy options in patients with HER2-low advanced breast
trastuzumab In 2006, trastuzumab plus chemotherapy was approved to treat patients after their HER2-overexpressing breast tumors were surgically removed
trastuzumab In the DESTINY-Breast04 trial, trastuzumab deruxtecan showed superior activity over standard chemotherapy options in patients with HER2-low advanced breast
In the DESTINY-Breast04 trial, trastuzumab deruxtecan showed superior activity over standard chemotherapy options in patients with HER2-low advanced breast